ELAN vs. KYMR: Elanco Animal Health vs. Kymera Therapeutics Stock Comparison
How do Elanco Animal Health (ELAN) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Elanco Animal Health (ELAN) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ELAN is classified in Pharmaceuticals while KYMR is classified in Biotechnology.
| Profile Item | ELAN | KYMR |
|---|---|---|
| Name | Elanco Animal Health Incorporated | Kymera Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Biotechnology |
| GICS Sub-Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 12.86 billion USD | 11.25 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | September 20, 2018 | August 21, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| Total Return (1Y) | 24.03% | 131.52% |
| Total Return (3Y, Annualized) | 37.47% | 111.65% |
| Total Return (5Y, Annualized) | -4.24% | 15.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| Volatility (1Y, Annualized) | 43.57% | 62.83% |
| Beta (5Y) | 1.65 | 2.00 |
| Max Drawdown (5Y) | -75.59% | -83.27% |
| Avg. Volume (3M) | 5.65M | 833.05K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| Sharpe Ratio (1Y) | 0.45 | 2.03 |
| Sortino Ratio (1Y) | 0.66 | 4.16 |
Profitability
ROE (TTM)
Elanco Animal Health (ELAN) has no ROE value reported for this period; Kymera Therapeutics (KYMR) reports a negative figure of -27.29%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Elanco Animal Health (ELAN) reports 6.64%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
Profitability Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| ROE (TTM) | -- | -27.29% |
| ROA (TTM) | -- | -17.64% |
| Net Margin (TTM) | -2.86% | 0.00% |
| Operating Margin (TTM) | 6.64% | -396.04% |
| Gross Margin (TTM) | 56.18% | 0.00% |
Growth
Revenue Growth
Elanco Animal Health (ELAN) at 6.22% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Elanco Animal Health (ELAN) reports EPS growth of -169.12%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.
Growth Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| Revenue Growth (YoY) | 6.22% | -16.70% |
| Revenue Growth (3Y CAGR) | 2.25% | -5.74% |
| EPS Growth (YoY) | -169.12% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Kymera Therapeutics (KYMR) shows current ratio of 11.13 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Elanco Animal Health (ELAN) at 0.64 and Kymera Therapeutics (KYMR) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| Current Ratio (MRQ) | -- | 11.13 |
| Debt / Equity (MRQ) | 0.64 | 0.05 |
| Net Debt / EBITDA | 3.49 | -- |
Dividends
Dividend Yield (TTM)
Neither Elanco Animal Health (ELAN) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Elanco Animal Health (ELAN) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Elanco Animal Health (ELAN) nor Kymera Therapeutics (KYMR) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Kymera Therapeutics (KYMR) at 110.00 prices above its industry range — a wide gap in sales valuation between them.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Elanco Animal Health (ELAN) at 1.95 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ELAN | KYMR |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.50 | 110.00 |
| P/B Ratio (MRQ) | 1.95 | 6.96 |
| Free Cash Flow Yield (TTM) | -- | -1.46% |